Insufficient immunological reconstitution is one of the serious complications of allogeneic stem cell transplantation (SCT). We report a case of severely impaired Blymphopoiesis after allogeneic SCT for CML. The patient's bone marrow and blood cells display complete chimerism and he is currently free from leukemia. His serum immunoglobulin levels are below detection level, and B cells are absent at 2 years post transplant in both the bone marrow and blood. Other populations appear to be normal. To the best of our knowledge, this is the first report of B-lymphopoiesis being undetectable more than 2 years after allogeneic SCT. Bone Marrow Transplantation (2002) 30, 397-400. doi:10.1038/sj.bmt.1703642 Keywords: agammaglobulinemia; allogeneic BMT; chronic GVHD Allogeneic stem cell transplantation (SCT) is one of the most powerful means for treating hematological disorders such as leukemia and severe aplastic anemia, but it has some life-threatening complications. Incomplete immune reconstitution and the resulting serious infections are among such complications. Recently, the factors influencing B-lymphopoiesis after allogeneic SCT were analyzed with the conclusion that post transplant B cell deficiency results in part from the inhibition of B-lymphopoiesis by GVHD and/or its treatment. 1 We report a case where Blymphopoiesis has remained undetectable more than 2 years after allogeneic SCT.
ated TBI (12 Gy) were used for conditioning. The number of infused nucleated cells was 1.9 ϫ 10 8 /kg body weight. Short-course methotrexate and cyclosporin A were used as GVHD prophylaxis. Engraftment was confirmed on day 24. Around that time, grade I acute GVHD (aGVHD) developed in the skin, which was treated by intravenous methylprednisolone (60 mg daily) followed by reduceddose oral prednisolone (PSL). Subsequently, the aGVHD improved. On day 38, cytomegalovirus (CMV) antigenemia became positive and gancyclovir (day 40-53, day 68-76) was administrated with a response. On day 100, extensivetype chronic GVHD (cGVHD) developed in the skin and the daily oral PSL was increased from 10 mg to 30 mg, following which the cGVHD subsided and PSL was tapered off. The patient was discharged on day 146. Herpes zoster occurred on day 160, which was treated with acyclovir. After this episode, he had no major infections until day 500 post BMT. Around day 500, he had a high fever with an unknown focus of infection, and antibiotics and ␥-globulin were administered with a response. Thereafter, 7.5 g of ␥-globulin was administered monthly until now. Hematological remission is maintained and bcr/abl chimeric mRNA remains negative based on RT-PCR. One hundred percent donor-type chimerism has also been confirmed by Y-chromosome fluorescence in situ hybridization (FISH) analysis. After BMT, his serum immunoglobulin levels began to decrease and reached undetectable levels on day 354 post transplant (Table 1) , where they remain currently (day 690). Flow cytometry analysis demonstrated that CD19 + B cells in his peripheral blood and bone marrow were absolutely absent on day 690 post transplant. The numbers of peripheral T cells (1.1 ϫ 10 9 /l) and NK cells (0.7 ϫ 10 9 /l) were /l. The bone marrow was normocellular and normal in morphology. Extensive-type cGVHD of the skin continues on 10 mg daily PSL.
Phenotypic assay and molecular analysis
Peripheral blood and bone marrow cells were obtained from the patient (15 months after BMT), three control patients and two healthy donors, with informed consent. Control patient 1 (Pt1) was a CML patient in the 2nd chronic phase (CP) and at 9 months after allogeneic BMT in complete remission (CR) without cGVHD. Control patient 2 (Pt2) was an AML (M2) patient in 1st CR, at 10 months after allogeneic BMT with extensive-type skin and liver cGVHD. Control patient 3 (Pt3) was a CML patient in 1st CP, at 7 months after allogeneic BMT in CR with limitedtype liver cGVHD. Cells were stained according to the standard procedures and analyzed by flow cytometry using the FACS calibur apparatus (Becton Dickinson, San Jose, CA, USA). Phycoerythrin (PE) conjugated anti-human IgG (679.1 MC7) and anti-human CD19 (J4.119) were purchased from Immunotech (Marseilles, France) and used to stain the cells. Expression of various B cell-related molecules in the patient presented and control patient 1 was evaluated by RT-PCR. In brief, total RNA was extracted from 1 ϫ 10 7 mononuclear cells according to the manufacture's protocol (Tri Reagent LS; Sigma, St Louis, MO, USA) and reverse-transcribed using random primers. The transcribed cDNA was subjected to PCR amplification using the following primers as described elsewhere:
,GAPDH (F 5Ј-ATGCTGGCGGCTGAGTAC-3Ј, R 5Ј-TGAGTCCTTCCACGATAC-3Ј). The PCR products were separated on agarose gels, and the fractionated cDNA was visualized by ethidium bromide staining.
Results and discussion
Flow cytometry analysis demonstrated that there were no detectable CD19
+ B cells in the patient's peripheral blood or bone marrow (Figure 1) . The RT-PCR-based expression profile of B cell-related molecules in the bone marrow cells is shown in Figure 2 . Expression levels of EBF and Pax5, lineage commitment from hematopoietic stem cells and that CD19 is expressed in the very early post commitment stage through B cell maturation, B-lineage cells are depleted through the maturation stages. In contrast, we observed that the numbers of myeloid, T and NK cells are within normal limits. Therefore, the depletion is restricted to the B cell lineage. This appears to indicate that the impairment is very specific to B-lymphopoiesis. To our surprise, the expression levels of Ig␤ and 5, which are a signal transduction molecule and a surrogate light chain that comprise the pre-B cell receptor together with the newly produced IgH protein, were similar in the bone marrow mononuclear cells of the patient presented and that of the control patient. Although CD19 is commonly used as the earliest marker for B-lineage cells, evidence has suggested that the commitment to B-lineage cells precedes CD19 expression [5] [6] [7] and that there are CD19
Ϫ B-lineage cells that express Ig␤ or 5 without CD19. Given this, B-lymphopoiesis is terminated or B-linBone Marrow Transplantation eage cells are disrupted before CD19 expression. There are multiple possible mechanisms which may cause this event, particularly in the presence of extensive-type chronic GVHD. Examples are that an excess of GVHD-associated cytokines such as interferon-␥ 8 and interleukin-1 9 may inhibit B-lymphopoiesis and that the donor lymphocytes may injure the patient's bone marrow stroma cells that are required for B-lymphopoiesis. 10 The cause of the post transplant B cell deficiency is indeed attributed, at least in part, to the inhibition of B-lymphopoiesis by GVHD and/or its treatment. 1 It is possible that auto-reactive T cells also participated in the injury of B-progenitor cells in this condition. Another small possibility is that the donor had an insidious B cell deficiency disorder or was a carrier, and only after BMT did it became evident in the recipient. Because of the privacy-oriented policy of the Japan Marrow Donor Program through which the donor was found, we could not examine the donor's serum IgG/IgA/IgM levels or B cells later. However, the serum total protein of the donor was normal (7.7 g/dl) and she had children, thus, we think the donor had a normal immune status, although there is a possibility that she was a carrier of an insidious B cell deficiency disorder.
In conclusion, we report a case of severe B cell deficiency after allogeneic SCT. Documentation of reduction in B cell numbers after HSCT is not rare, but to our knowledge this is the first report describing the complete loss in B-lineage cells after CD19 expression accompanying agammaglobulinemia.
